Dietary vitamin D and vitamin D receptor level modulate epithelial cell proliferation and apoptosis in the prostate

Cancer Prevention Research

Volumn 4, Issue 10, 2011, Pages 1617-1625

  Kovalenko, Pavlo L ^a,c   Zhang, Zhentao ^a,d   Yu, Jun Ge ^b   Li, Yan ^a   Clinton, Steven K ^b   Fleet, James C ^a  

^a Purdue University   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; COLECALCIFEROL; KI 67 ANTIGEN; TESTOSTERONE PROPIONATE; VITAMIN D RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CASTRATION; CELL PROLIFERATION; CONTROLLED STUDY; MALE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATIC INTRAEPITHELIAL NEOPLASIA; WILD TYPE;

ANDROGENS; ANIMALS; APOPTOSIS; CALCIUM; CASTRATION; CELL PROLIFERATION; CELLS, CULTURED; DIET; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; MICE, TRANSGENIC; PROSTATE; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 80053910848     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0035     Document Type: Article

References (49)

1. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992;70:2861-9.
2. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000;11:847-52.
3. Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993;2:467-72.
4. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 2008;100:796-804. (Pubitemid 351809669)
5. Margolis RN, Christakos S. The nuclear receptor superfamily of steroid hormones and vitamin D gene regulation. An update. Ann N Y Acad Sci 2010;1192:208-14.
6. Kivineva M, Blauer M, Syvala H, Tammela T, Tuohimaa P. Localization of 1,25-dihydroxyvitamin D-3 receptor (VDR) expression in human prostate. J Steroid Biochem Mol Biol 1998;66:121-7. (Pubitemid 28366037)
7. Hedlund TE, Moffatt KA, Miller GJ. Vitamin D receptor expression is required for growth modulation by 1 alpha, 25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol 1996;58:277-88. (Pubitemid 26301120)
8. Zhuang SH, Schwartz GG, Cameron D, Burnstein KL. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 1997;126:83-90. (Pubitemid 27055550)
9. Banach-Petrosky W, Ouyang X, Gao H, Nader K, Ji Y, Suh N, et al. Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1; Pten mutant mice. Clin Cancer Res 2006;12:5895-901. (Pubitemid 44629623)
10. Guns ES, Xie X, Fedoruk M, Madera C, Cowell S, Mayer LD, et al. pH modulation using CsCl enhances therapeutic effects of vitamin D in LNCaP tumor bearing mice. Prostate 2005;64:316-22. (Pubitemid 40980873)
11. Yin Y, Ni J, Chen M, Guo Y, Yeh S. RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects. Clin Cancer Res 2009;15:190-200.
12. Need AG, O'Loughlin PD, Morris HA, Coates PS, Horowitz M, Nordin BE. Vitamin D metabolites and calcium absorption in severe vitamin D deficiency. J Bone Miner Res 2008;23:1859-63.
13. Sporn MB, Suh N. Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer 2002;2:537-43. (Pubitemid 37328935)
14. Sakr WA, Sarkar FH, Sreepathi P, Drozdowicz S, Crissman JD. Measurement of cellular proliferation in human prostate by AgNOR, PCNA, and SPF. Prostate 1993;22:147-54. (Pubitemid 23120791)
15. Colombel MC, Buttyan R. Hormonal control of apoptosis: the rat prostate gland as a model system. Methods Cell Biol 1995;46:369-85.
16. Hill R, Song Y, Cardiff RD, Van Dyke T. Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model. Cancer Res 2005;65:10243-54. (Pubitemid 41743716)
17. Reeves PG, Nielsen FH, Fahey GC. AIN-93 purified diets for laboratory rodents: Final report of the american institute of nutrition Ad Hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993;123:1939-51. (Pubitemid 23342492)
18. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004;64:2270-305. (Pubitemid 38339483)
19. Suttie A, Nyska A, Haseman JK, Moser GJ, Hackett TR, Goldsworthy TL. A grading scheme for the assessment of proliferative lesions of the mouse prostate in the TRAMP model. Toxicol Pathol 2003;31:31-8. (Pubitemid 36169419)
20. Fleet JC, Gliniak C, Zhang Z, Xue Y, Smith KB, McCreedy R, et al. Serum metabolite profiles and target tissue gene expression define the effect of cholecalciferol intake on calcium metabolism in rats and mice. J Nutr 2008;138:1114-20. (Pubitemid 351769138)
21. Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ, et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 2001;101:61-9. (Pubitemid 32186310)
22. Cunha GR. Mesenchymal-epithelial interactions: past, present, and future. Differentiation 2008;76:578-86. (Pubitemid 352032745)
23. Fleet JC. Molecular actions of vitamin D contributing to cancer prevention. Mol Aspects Med 2008;29:388-96.
24. Xue L, Yang K, Newmark H, Lipkin M. Induced hyperproliferation in epithelial cells of mouse prostate by a Western-style diet. Carcinogenesis 1997;18:995-9. (Pubitemid 28132345)
25. Vieth R, Fraser D, Kooh SW. Low dietary calcium reduces 25-hydroxycholecalciferol in plasma of rats. J Nutr 1987;117:914-8. (Pubitemid 17093572)
26. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994;54:805-10. (Pubitemid 24068341)
27. Kovalenko PL, Zhang Z, Cui M, Clinton SK, Fleet JC. 1,25 dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1. BMC Genomics 2010;11:26.
28. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1 alpha, 25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1995;1:997-1003.
29. Guzey M, Kitada S, Reed JC. Apoptosis induction by 1 alpha, 25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther 2002;1:667-77.
30. Berkovich L, Ben-Shabat S, Sintov AC. Induction of apoptosis and inhibition of prostate and breast cancer growth by BGP-15, a new calcipotriene-derived vitamin D3 analog. Anticancer Drugs 2010;21:609-18.
31. Crescioli C, Ferruzzi P, Caporali A, Scaltriti M, Bettuzzi S, Mancina R, et al. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur J Endocrinol 2004;150:591-603. (Pubitemid 38584712)
32. Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, Sanvito F, et al. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol 2006;177:8504-11. (Pubitemid 44895295)
33. Oades GM, Dredge K, Kirby RS, Colston KW. Vitamin D receptordependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int 2002;90:607-16.
34. Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 1998;7:391-5. (Pubitemid 28354127)
35. Barreto AM, Schwartz GG, Woodruff R, Cramer SD. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev 2000;9:265-70. (Pubitemid 30165438)
36. Kallay E, Pietschmann P, Toyokuni S, Bajna E, Hahn P, Mazzucco K, et al. Characterization of a vitamin D receptor knockout mouse as a model of colorectal hyperproliferation and DNA damage. Carcinogenesis 2001;22:1429-35. (Pubitemid 32898700)
37. Zinser GM, Suckow M, Welsh J. Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues. J Steroid Biochem Mol Biol 2005;97:153-64. (Pubitemid 41546225)
38. Boyle BJ, Zhao XY, Cohen P, Feldman D. Insulin-like growth factor binding protein-3 mediates 1 alpha,25- dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 2001;165:1319-24. (Pubitemid 32210283)
39. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 2001;154:369-87. (Pubitemid 34286147)
40. Blutt SE, McDonnell TJ, Polek TC, Weigel NL. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 2000;141:10-7. (Pubitemid 32260340)
41. Myrthue A, Rademacher BL, Pittsenbarger J, Kutyba-Brooks B, Gantner M, Qian DZ, et al. The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells. Clin Cancer Res 2008;14:3562-70.
42. Lou YR, Miettinen S, Kagechika H, Gronemeyer H, Tuohimaa P. Retinoic acid via RARalpha inhibits the expression of 24-hydroxylase in human prostate stromal cells. Biochem Biophys Res Commun 2005;338:1973-81. (Pubitemid 41643115)
43. Niu YN, Xia SJ. Stroma-epithelium crosstalk in prostate cancer. Asian J Androl 2009;11:28-35.
44. Ting HJ, Bao BY, Hsu CL, Lee YF. Androgen-receptor coregulators mediate the suppressive effect of androgen signals on vitamin D receptor activity. Endocrine 2005;26:1-9.
45. Zhao XY, Ly LH, Peehl DM, Feldman D. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgendependent. Endocrinology 1997;138:3290-8. (Pubitemid 27345681)
46. Zhao XY, Peehl DM, Navone NM, Feldman D. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 2000;141:2548-56. (Pubitemid 32269075)
47. Murthy S, Agoulnik IU, Weigel NL. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate 2005;64:362-72. (Pubitemid 41193249)
48. Serpa NA, Tobias-Machado M, Esteves MA, Senra MD, Wroclawski ML, Fonseca FL, et al. A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma. BMC Urol 2010;10:9.
49. Francis RM, Peacock M, Aaron JE, Selby PL, Taylor GA, Thompson J, et al. Osteoporosis in hypogonadal men: role of decreased plasma 1,25-dihydroxyvitamin D, calcium malabsorption, and low bone formation. Bone 1986;7:261-8. (Pubitemid 17195784)